[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f2fe842lmnjakw":3},{"data":4,"error":10},{"id":5,"documentId":6,"heading":7,"body":8,"slug":9,"name":9,"name_ar":10,"proprietary_name":10,"non_proprietary_name":10,"is_proprietary":10,"active_ingredient":10,"administration_route":10,"available_strength":10,"dosage_form":10,"dose_schedule":10,"drug_unit":10,"is_available_generically":10,"mechanism_of_action":10,"overdosage":10,"warning":10,"species":11,"citations":12,"dose_schedules":42,"available_strengths":65,"label_statements":78,"drug_classes":98,"specialties":104,"medical_conditions":105,"animal_species":130},1938,"vmr1amidiikn44p5wfuwkk04","إيميدوكارب","الإيميدوكارب (imidocarb) مضاد للأواليات تصفه الوكالة الأوروبية للأدوية (EMA) بأنه مشتق من الكاربانيليد، ويُعطى عادةً في صورة ملح ثنائي البروبيونات. يُستعمل الإيميدوكارب في الطب البيطري لمكافحة طفيليات البابيزيا، بحسب ملخص خصائص المستحضر (SPC) لمستحضره المرخّص في بريطانيا.\n\n## آلية العمل\n\nتصف الوكالة الأوروبية للأدوية (EMA) آلية عمل الإيميدوكارب بأنها غير مؤكدة، وتذكر آليتين مقترحتين: التدخل في إنتاج متعددات الأمين أو استعمالها، أو منع دخول الإينوزيتول إلى كرية الدم الحمراء التي يسكنها الطفيلي. يقرّ ملخص خصائص المستحضر (SPC) البريطاني بأن المعروف عن آلية عمل الإيميدوكارب قليل، ويذكر أن الإيميدوكارب يبدو مؤثرًا مباشرة في الطفيلي، فيغيّر عدد أنويته وحجمها ويُحدث فجوات في سيتوبلازمه. ينسب ملخص خصائص المستحضر (SPC) نفسه النشاط المضاد للأواليات إلى تأثير الكاربانيليد في عملية تحلل السكر لدى الطفيلي. يذكر ملخص خصائص المستحضر (SPC) أن ثنائي بروبيونات الإيميدوكارب طويل مدة التأثير لارتباطه ببروتينات البلازما والأنسجة، وأنه ضعيف الامتصاص عند إعطائه فمويًا.\n\n## الاستعمالات البيطرية والأنواع الحيوانية\n\nيخصص ملخص خصائص المستحضر (SPC) البريطاني الإيميدوكارب للأبقار وحدها، لعلاج [داء البابيزيات البقري](\u002Fmedical-conditions\u002Fbovine-babesiosis) المعروف بحمى الماء الأحمر والناجم عن Babesia divergens والوقاية منه. يذكر دليل MSD البيطري أن عقاقير كثيرة قاتلة للبابيزيا استُعملت لعلاج داء البابيزيات البقري، لكن ثنائي بروبيونات الإيميدوكارب وأسيتورات الديمينازين وحدهما ما زالا شائعي الاستعمال، مع أنهما غير متوفرين في كل البلدان الموبوءة أو قد يكون استعمالهما مقيدًا. يذكر دليل MSD البيطري الإيميدوكارب إلى جانب التتراسيكلينات بين العلاجات الرئيسية لـ[داء الأنابلازما البقري](\u002Fmedical-conditions\u002Fbovine-anaplasmosis)، وهو مرض ينقله القراد ويصيب المجترات بجراثيم داخل خلوية تغزو كريات الدم الحمراء فتسبب الحمى وفقر الدم. في الكلاب، ينبه دليل MSD البيطري إلى أن Babesia gibsoni، وهي بابيزيا صغيرة الحجم، تسبب مرضًا مزمنًا مع فقر دم شديد متفاقم لا يستجيب بسهولة لمضادات البابيزيا المعتادة.\n\n## السلامة\n\nتذكر الوكالة الأوروبية للأدوية (EMA) أن المؤشر العلاجي للإيميدوكارب ضيق في الأنواع المستهدفة، وأن علامات التسمم به نُسبت إلى تأثيره المثبط لإنزيم الكولينستراز. يذكر ملخص خصائص المستحضر (SPC) البريطاني أن الإيميدوكارب يعبر المشيمة لدى الأبقار الحوامل المعالجة، لكن لا يبدو أن له تأثيرًا ضارًا في الجنين أو العجل.\n\n## الوضع التنظيمي\n\nيحمل مستحضر الإيميدوكارب المخصص للكلاب في الولايات المتحدة موافقة مركز الطب البيطري في إدارة الغذاء والدواء الأمريكية (FDA CVM) بموجب طلب دواء حيواني جديد. يصنّف ملخص خصائص المستحضر (SPC) المنشور لدى مديرية الأدوية البيطرية في المملكة المتحدة (VMD) مستحضر الإيميدوكارب المخصص للأبقار دواءً بيطريًا لا يُصرف إلا بوصفة.","imidocarb",null,[],[13,19,23,30,33,36,39],{"source":14,"licence":15,"source_url":16,"harvested_by":17,"retrieved_at":18},"FDA Green Book","US public domain","https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002FingredientsInformationExcel\u002FSection2ActiveIngredients","load-reference-corpus.cjs","2026-09-07",{"source":20,"licence":21,"source_url":22,"harvested_by":17,"retrieved_at":18},"UK VMD PID","OGL v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002Fproductinformationdatabase\u002Fdownloads\u002Fvmd_productinformationdatabase.xlsx",{"claims":24,"source":25,"licence":26,"source_url":27,"harvested_by":28,"retrieved_at":29},"Arabic article (body)","EMA CVMP Imidocarb Summary Report (2)","facts cited; the Arabic article is original text","https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fdocuments\u002Fmrl-report\u002Fimidocarb-summary-report-2-committee-veterinary-medicinal-products_en.pdf","apply-chain-articles.cjs","2026-10-14",{"claims":24,"source":31,"licence":26,"source_url":32,"harvested_by":28,"retrieved_at":29},"UK VMD SPC, Imizol 85 mg\u002Fml Solution for Injection","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002Fproductinformationdatabase\u002Ffiles\u002FSPC_Documents\u002FSPC_81806.PDF",{"claims":24,"source":34,"licence":26,"source_url":35,"harvested_by":28,"retrieved_at":29},"Merck Veterinary Manual, Babesiosis in Animals","https:\u002F\u002Fwww.merckvetmanual.com\u002Fcirculatory-system\u002Fblood-parasites\u002Fbabesiosis-in-animals",{"claims":24,"source":37,"licence":26,"source_url":38,"harvested_by":28,"retrieved_at":29},"Merck Veterinary Manual, Anaplasmosis in Ruminants","https:\u002F\u002Fwww.merckvetmanual.com\u002Fcirculatory-system\u002Fblood-parasites\u002Fanaplasmosis-in-ruminants",{"claims":24,"source":40,"licence":26,"source_url":41,"harvested_by":28,"retrieved_at":29},"DailyMed (NLM), Imizol label","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=c7bfe38c-9249-466d-8718-8b8e82b99a8d",[43,50,57,60],{"id":44,"dose_text":45,"species":46,"administration_route":47,"limitation":48,"source_label":49},14692,"Use intramuscularly or subcutaneously at a rate of 6.6 mg\u002Fkg (3mg\u002Flb) body\nweight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.","Dogs","Intramuscular, Subcutaneous","Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.\nMust not be administered intravenously.\nThe safety and effectiveness of imidocarb have not been determined in puppies or in breeding, lactating, or pregnant animals.\nDo not use this product simultaneously with exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.","Imizol®",{"id":51,"dose_text":52,"species":53,"administration_route":54,"limitation":55,"source_label":56},14693,"For Babesia caballi infections, use intramuscularly 2 milligrams of imidocarb base per kilogram of body weight, repeating dosage once after 24 hours. For Babesia equi infections, use 4 milligrams of imidocarb base per kilogram of body weight, repeating dosage four times at 72-hour intervals. Administer intramuscularly in the neck region.","Zebras","Intramuscular","Do not inject intravenously. Do not use for other Equidae or for animals of other species. Do not use in horses less than 1 year old. Do not use for animals in near-term pregnancies. Imidocarb dipropionate is a cholinesterase inhibitor. Do not use this product simultaneously with or a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals. Do not use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Imidocarb dipropionate is sold only under permit issued by the Director of the National Program Planning Staff, Veterinary Services APHIS, USDA, to licensed or full-time State, Federal or military veterinarians.","Imizol® Equine Injection",{"id":58,"dose_text":52,"species":59,"administration_route":54,"limitation":55,"source_label":56},14694,"Horses",{"id":61,"dose_text":62,"species":10,"administration_route":63,"limitation":10,"source_label":64},14695,"Use intramuscularly or subcutaneously at a rate of 6.6 mg\u002Fkg (3mg\u002Flb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.\nIMIZOL® DOSING GUIDE 6.6 mg\u002Fkg Body Weight\nAnimal Weight\nIMIZOL Dosage\nAnimal Weight\nIMIZOL Dosage\n10 lb (4.5 kg)\n0.25 mL\n60 lb (27.3 kg)\n1.50 mL\n20 lb (9.1 kg)\n0.50 mL\n80 lb (36.4 kg)\n2.00 mL\n30 lb (13.6 kg)\n0.75 mL\n100 lb (45.5 kg)\n2.50 mL\n40 lb (18.2 kg)\n1.00 mL","SUBCUTANEOUS, INTRAMUSCULAR","Imizol® (IMIDOCARB DIPROPIONATE)",[66,70,73,75],{"id":67,"strength_text":68,"dosage_form":69,"proprietary_name":49,"species":46,"source_label":49},12737,"Each mL contains 120 mg of imidocarb dipropionate.","Liquid (Solution)",{"id":71,"strength_text":72,"dosage_form":69,"proprietary_name":56,"species":53,"source_label":56},12738,"Imidocarb dipropionate powder is reconstituted with sterile water. Each milliliter of solution contains 100 milligrams of imidocarb base.",{"id":74,"strength_text":72,"dosage_form":69,"proprietary_name":56,"species":59,"source_label":56},12739,{"id":76,"strength_text":77,"dosage_form":10,"proprietary_name":10,"species":10,"source_label":64},12740,"120 mg \u002F 1 mL",[79,83,86,88,90,94],{"id":80,"kind":81,"statement":82,"species":46,"limitation":48,"source_label":49},21611,"indication","For the treatment of dogs with clinical signs of babesiosis and\u002For demonstrated Babesia organisms in the blood.",{"id":84,"kind":81,"statement":85,"species":53,"limitation":55,"source_label":56},21612,"For the treatment of babesiosis (piroplasmosis) caused by Babesia caballi and Babesia equi.",{"id":87,"kind":81,"statement":85,"species":59,"limitation":55,"source_label":56},21613,{"id":89,"kind":81,"statement":82,"species":10,"limitation":10,"source_label":64},21614,{"id":91,"kind":92,"statement":93,"species":10,"limitation":10,"source_label":64},21615,"warning","WARNING: NOT FOR HUMAN USE. KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. IN THE EVENT OF HUMAN EXPOSURE IMMEDIATELY CALL 303-595-4869, FOR MEDICAL ADVICE FOR HUMANS. Oncogenesis: Increased incidence of tumors was observed in rats given imidocarb.",{"id":95,"kind":96,"statement":97,"species":10,"limitation":10,"source_label":64},21616,"adverse_reaction","Adverse effects commonly seen are pain during injection and mild cholinergic signs such as salivation, nasal drip, or brief episodes of vomiting. Other effects seen less frequently are panting, restlessness, diarrhea, and mild injection site inflammation lasting one to several days. Rarely, injection site ulceration occurs, but the lesion is not resistant to healing.\nIf sever cholinergic signs occur, they may be reversed with atropine sulfate.\nTo report an adverse reaction, product-related problem, human exposure, or to obtain a copy of the Safety Data Sheet (SDS), please call Merck Animal Health Technical Services at 1-800-224-5318.\nFor additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDAVETS or http:\u002F\u002Fwww.fda.gov\u002Freportanimalae.",[99],{"id":100,"documentId":101,"slug":102,"name":103,"heading":10},796,"yya06yeemmy6882ot6dngain","carbanilide-antiprotozoals","Carbanilide antiprotozoals",[],[106,112,118,124],{"id":107,"documentId":108,"slug":109,"title":110,"heading":111},292,"q225am7ruy203o7rjgq507pa","bovine-anaplasmosis","Bovine anaplasmosis","داء الأنابلازما البقري",{"id":113,"documentId":114,"slug":115,"title":116,"heading":117},265,"c99dx7js0n5kety3tqvff943","bovine-babesiosis","Bovine babesiosis","داء البابيزيات البقري",{"id":119,"documentId":120,"slug":121,"title":122,"heading":123},295,"wrq5fe322uwafy951gobt84y","infection-with-theileria-equi-and-babesia-caballi-equine","Infection with Theileria equi and Babesia caballi (Equine piroplasmosis)","داء الكمثريات الخيلي",{"id":125,"documentId":126,"slug":127,"title":128,"heading":129},293,"cjkmjqu2zevxweofeb9inwzc","anaplasmosis","Anaplasmosis","داء الأنابلازما",[]]